Stock Analysis

Arzneiwerk VIDA Third Quarter 2024 Earnings: €0.044 loss per share (vs €0.12 loss in 3Q 2023)

Simply Wall St

Published December 04, 2024

Arzneiwerk VIDA (ETR:TLIK) Third Quarter 2024 Results

Key Financial Results

Revenue: €14.8m (flat on 3Q 2023).
Net loss: €272.0k (loss narrowed by 64% from 3Q 2023).
€0.044 loss per share (improved from €0.12 loss in 3Q 2023).

XTRA:TLIK Earnings and Revenue History December 4th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Arzneiwerk VIDA shares are up 4.2% from a week ago.

Risk Analysis

We should say that we've discovered 4 warning signs for Arzneiwerk VIDA that you should be aware of before investing here.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.